NG11-1 - VasoDynamics

NG11 Prevention and Reduction Of Radiation – induced Oral Mucositis (RIOM)

VasoDynamics Undertakes Pivotal Trial Scientific Advisory Meeting with Regulatory Authority in the Netherlands to Discuss Next Steps in NG11-2 Development Programme
Gallery

VasoDynamics Undertakes Pivotal Trial Scientific Advisory Meeting with Regulatory Authority in the Netherlands to Discuss Next Steps in NG11-2 Development Programme

By Chloe Atkinson|2024-11-13T12:56:20+00:00October 18th, 2024|Clinical Development, News, NG11|

NG11-2 Phase-Ib Study Completes Last Patient Visit
Gallery

NG11-2 Phase-Ib Study Completes Last Patient Visit

By Chloe Atkinson|2024-11-13T12:57:16+00:00August 21st, 2024|Clinical Development, News, NG11|

NG11-2 Phase-Ib Study Closes Enrolment – Results Expected Autumn 2024
Gallery

NG11-2 Phase-Ib Study Closes Enrolment – Results Expected Autumn 2024

By Chloe Atkinson|2024-11-13T12:57:26+00:00July 1st, 2024|Clinical Development, News, NG11|

VasoDynamics Presents Phase-1b NG11-2 Clinical Data at ESTRO Conference
Gallery

VasoDynamics Presents Phase-1b NG11-2 Clinical Data at ESTRO Conference

By Chloe Atkinson|2024-11-13T12:57:42+00:00May 9th, 2024|Clinical Development, News, NG11|

NG11-2 Phase-Ib Dose Escalation Phase Completes & Dose Expansion Cohort Open to Enrolment
Gallery

NG11-2 Phase-Ib Dose Escalation Phase Completes & Dose Expansion Cohort Open to Enrolment

By Chloe Atkinson|2024-12-05T11:10:16+00:00March 4th, 2024|Clinical Development, News, NG11|

NG11-2 Phase Ib Dose Escalation Clinical Study Progressing through Dose Levels
Gallery

NG11-2 Phase Ib Dose Escalation Clinical Study Progressing through Dose Levels

By Chloe Atkinson|2024-11-13T12:59:13+00:00October 16th, 2023|Clinical Development, News, NG11|

First dose cohort completed and enrolment to second dose cohort commenced in NG11-2 Phase-Ib clinical trial
Gallery

First dose cohort completed and enrolment to second dose cohort commenced in NG11-2 Phase-Ib clinical trial

By Chloe Atkinson|2024-11-13T14:09:14+00:00July 28th, 2023|Clinical Development, News, NG11|

First patient dosed for the first week in NG11-2 Phase Ib clinical trial
Gallery

First patient dosed for the first week in NG11-2 Phase Ib clinical trial

By Chloe Atkinson|2024-11-13T12:59:46+00:00May 26th, 2023|Clinical Development, News, NG11|

First patient enrolled in NG11-2 Phase Ib clinical trial
Gallery

First patient enrolled in NG11-2 Phase Ib clinical trial

By Chloe Atkinson|2024-11-13T13:00:15+00:00May 8th, 2023|Clinical Development, News, NG11|

VasoDynamics Receives UK MHRA-REC Approval On NG11-2 Phase Ib Clinical Trial
Gallery

VasoDynamics Receives UK MHRA-REC Approval On NG11-2 Phase Ib Clinical Trial

By Chloe Atkinson|2024-11-13T13:00:29+00:00January 24th, 2023|Clinical Development, News, NG11|